Quick Answer
Alto Neuroscience, Inc. reported Cash and Equivalents of $176.48 million for fiscal year 2025.
Alto Neuroscience, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $176.48M | +4.9% |
| 2024 | $168.23M | +103.8% |
| 2023 | $82.55M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $137.82M | -24.2% | -6.6% |
| June 30, 2025 | $147.59M | -23.6% | -8.2% |
| March 31, 2025 | $160.75M | -21.9% | -4.4% |
| December 31, 2024 | $168.23M | +103.8% | -7.4% |
| September 30, 2024 | $181.70M | — | -5.9% |
| June 30, 2024 | $193.12M | — | -6.2% |
| March 31, 2024 | $205.90M | — | +149.4% |
| December 31, 2023 | $82.55M | — | — |
- Alto Neuroscience, Inc. showed an increase of +4.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Alto Neuroscience, Inc.’s cash and equivalents has grown by 113.8% (from $82.55 million to $176.48 million).
- The most recent figure is from Alto Neuroscience, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: